Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Stock Price Crosses Above 200 Day Moving Average – What’s Next?

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) shares passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $36.98 and traded as high as $45.00. Global X Genomics & Biotechnology ETF shares last traded at $44.93, with a volume of 4,734 shares traded.

Global X Genomics & Biotechnology ETF Stock Up 3.0%

The company has a market capitalization of $54.81 million, a PE ratio of -19.20 and a beta of 1.22. The firm’s 50 day simple moving average is $41.75 and its 200 day simple moving average is $36.98.

Institutional Trading of Global X Genomics & Biotechnology ETF

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in GNOM. Oxinas Partners Wealth Management LLC boosted its holdings in Global X Genomics & Biotechnology ETF by 12.1% during the 2nd quarter. Oxinas Partners Wealth Management LLC now owns 16,212 shares of the company’s stock valued at $137,000 after acquiring an additional 1,751 shares during the period. Atria Investments Inc lifted its position in shares of Global X Genomics & Biotechnology ETF by 12.6% during the second quarter. Atria Investments Inc now owns 18,520 shares of the company’s stock worth $156,000 after purchasing an additional 2,073 shares during the last quarter. HighTower Advisors LLC boosted its stake in shares of Global X Genomics & Biotechnology ETF by 16.7% during the first quarter. HighTower Advisors LLC now owns 15,242 shares of the company’s stock valued at $121,000 after purchasing an additional 2,184 shares during the period. Smartleaf Asset Management LLC boosted its stake in shares of Global X Genomics & Biotechnology ETF by 18.5% during the first quarter. Smartleaf Asset Management LLC now owns 14,933 shares of the company’s stock valued at $125,000 after purchasing an additional 2,329 shares during the period. Finally, Private Advisor Group LLC grew its holdings in shares of Global X Genomics & Biotechnology ETF by 14.3% in the first quarter. Private Advisor Group LLC now owns 20,738 shares of the company’s stock worth $165,000 after purchasing an additional 2,587 shares during the last quarter. 56.95% of the stock is owned by hedge funds and other institutional investors.

About Global X Genomics & Biotechnology ETF

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.